CA2940225C - 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds - Google Patents

6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds Download PDF

Info

Publication number
CA2940225C
CA2940225C CA2940225A CA2940225A CA2940225C CA 2940225 C CA2940225 C CA 2940225C CA 2940225 A CA2940225 A CA 2940225A CA 2940225 A CA2940225 A CA 2940225A CA 2940225 C CA2940225 C CA 2940225C
Authority
CA
Canada
Prior art keywords
compound
compounds
benzo
dihydro
oxazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2940225A
Other languages
English (en)
French (fr)
Other versions
CA2940225A1 (en
Inventor
Sergio Luiz Sacurai
Carlos Eduardo Da Costa Touzarim
Fabiano Travanca TOLEDO
Bruno Artur De Sousa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolab Sanus Farmaceutica Ltda
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of CA2940225A1 publication Critical patent/CA2940225A1/en
Application granted granted Critical
Publication of CA2940225C publication Critical patent/CA2940225C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2940225A 2014-02-24 2015-02-24 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds Active CA2940225C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943825P 2014-02-24 2014-02-24
US61/943,825 2014-02-24
PCT/BR2015/000023 WO2015123748A1 (pt) 2014-02-24 2015-02-24 "NOVOS COMPOSTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO [3,4-a] PIRAZINA-5,8-DIONA "

Publications (2)

Publication Number Publication Date
CA2940225A1 CA2940225A1 (en) 2015-08-27
CA2940225C true CA2940225C (en) 2021-12-28

Family

ID=53877456

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2940225A Active CA2940225C (en) 2014-02-24 2015-02-24 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds

Country Status (19)

Country Link
US (1) US9359378B2 (pt)
EP (1) EP3133072B1 (pt)
JP (1) JP6636463B2 (pt)
KR (1) KR102408431B1 (pt)
AR (1) AR099523A1 (pt)
AU (1) AU2015221431B2 (pt)
BR (1) BR112016019609B1 (pt)
CA (1) CA2940225C (pt)
CL (1) CL2016002125A1 (pt)
ES (1) ES2734063T3 (pt)
HU (1) HUE044993T2 (pt)
IL (1) IL247330B (pt)
MX (1) MX369840B (pt)
PL (1) PL3133072T3 (pt)
PT (1) PT3133072T (pt)
TR (1) TR201910896T4 (pt)
UY (1) UY36010A (pt)
WO (1) WO2015123748A1 (pt)
ZA (1) ZA201606522B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114158266A (zh) * 2019-07-15 2022-03-08 生物实验萨纽斯药物有限公司 化合物3-(苯并[d][1,3]二氧杂环戊烯-5-基)-7-(1-羟基丙-2-基)-1-(1H-吲哚-3-基)-6,7-二氢-3H-噁唑并[3,4-a]吡嗪-5,8-二酮的立体异构体及其作为抗肿瘤剂和磷酸二酯酶抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098877A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
AR073522A1 (es) * 2008-09-30 2010-11-10 Biolab Sanus Farmaceutica Ltda Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
BRPI0903803B1 (pt) * 2009-09-30 2019-07-09 Biolab Sanus Farmacêutica Ltda. Composto, processo de preparação, composição farmacêutica e uso dos compostos
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona

Also Published As

Publication number Publication date
PL3133072T3 (pl) 2019-10-31
EP3133072A1 (en) 2017-02-22
HUE044993T2 (hu) 2019-11-28
JP6636463B2 (ja) 2020-01-29
IL247330B (en) 2020-10-29
CL2016002125A1 (es) 2016-12-30
AU2015221431A1 (en) 2016-09-29
TR201910896T4 (tr) 2019-08-21
WO2015123748A1 (pt) 2015-08-27
KR20160116028A (ko) 2016-10-06
BR112016019609B1 (pt) 2022-06-14
MX2016010912A (es) 2016-11-30
EP3133072B1 (en) 2019-05-01
JP2017506263A (ja) 2017-03-02
AR099523A1 (es) 2016-07-27
EP3133072A4 (en) 2017-08-09
PT3133072T (pt) 2019-07-26
BR112016019609A2 (pt) 2017-08-22
AU2015221431B2 (en) 2018-04-19
KR102408431B1 (ko) 2022-06-13
ZA201606522B (en) 2018-04-25
UY36010A (es) 2015-09-30
US9359378B2 (en) 2016-06-07
ES2734063T3 (es) 2019-12-04
AU2015221431A8 (en) 2016-11-24
IL247330A0 (en) 2016-09-29
CA2940225A1 (en) 2015-08-27
US20150239903A1 (en) 2015-08-27
MX369840B (es) 2019-11-22

Similar Documents

Publication Publication Date Title
JP4603885B2 (ja) アルキル置換ピラゾロピリミジン類
TWI663169B (zh) Ｃｄｋ２／４／６抑制劑
JP4757491B2 (ja) フェニル置換ピラゾロピリミジン類
CA3004372C (en) Pyrimidine derivative and use thereof
KR101811938B1 (ko) FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체
US8822479B2 (en) 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines
US20040048849A1 (en) Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
JP2014505091A (ja) ６−シクロブチル−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａ阻害剤としてのその使用
JP4889480B2 (ja) ６−アリールメチル置換ピラゾロピリミジン類
JP2006525966A (ja) ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類
JP6285610B2 (ja) アゼチジニルオキシフェニルピロリジン化合物
AU2014241444B2 (en) Azetidinyloxyphenylpyrrolidine compounds
JP5277303B2 (ja) ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類
US20080318949A1 (en) Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use
CA2940225C (en) 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds
WO2025190424A1 (zh) 一种3,8-双取代腺嘌呤衍生物、制备方法及其应用
AU2017283407A1 (en) Substituted tricyclic heterocyclic compounds and use thereof
US12180210B2 (en) Compounds
HK1212695B (en) Azetidinyloxyphenylpyrrolidine compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191210

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241212

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20251031

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20251031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251031

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20260317

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260407